Loading...
VLA logo

Valneva SEENXTPA:VLA 주식 보고서

시가총액 €438.5m
주가
€2.31
€3.25
28.9% 저평가 내재 할인율
1Y-20.5%
7D-0.1%
포트폴리오 가치
​
보기

Valneva SE

ENXTPA:VLA 주식 리포트

시가총액: €438.5m

Valneva (VLA) 주식 개요

백신 전문 기업인 발네바 SE는 미충족 수요가 있는 감염병 예방 백신을 개발, 제조 및 상용화하는 기업입니다. 자세히 보기

VLA 펀더멘털 분석
스노우플레이크 점수
가치 평가2/6
미래 성장5/6
과거 실적0/6
재무 건전성3/6
배당0/6

강점

수익은 매년 57.79% 증가할 것으로 예상됩니다.

위험 분석

지난 3개월 동안 주가 변동성이 French 시장과 비교했을 때 매우 높았습니다.


VLA Community Fair Values

Create Narrative

See what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.3% 저평가 내재 할인율
5022.2%Revenue growth p.a.
3.7k
23
2
54
29d ago

Valneva SE 경쟁사

가격 이력 및 성과

Valneva 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가€2.31
52주 최고가€5.42
52주 최저가€2.27
베타1.53
1개월 변동-14.69%
3개월 변동-40.54%
1년 변동-20.50%
3년 변동-60.95%
5년 변동-81.22%
IPO 이후 변동-78.91%

최근 뉴스 및 업데이트

VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback

Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.

VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time

Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).

Recent updates

VLA: Lyme Vaccine Progress Will Support Earnings Despite Chikungunya Setback

Analysts have kept their Valneva price target steady at €3.25, citing updated assumptions for discount rate, revenue growth, profit margins and future P/E that broadly support the prior valuation level. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial results for their 6-valent OspA-based Lyme disease vaccine candidate PF-07307405, with efficacy above 70% in reducing confirmed Lyme cases in two pre specified analyses and no safety concerns identified at the time of analysis.

VLA: Lyme Vaccine Progress Will Offset Chikungunya Headwinds Over Time

Analysts have raised their Valneva price target from €2.95 to €3.25, citing updated assumptions around revenue growth, profit margins, and a slightly lower future P/E multiple as the main factors behind the change. What's in the News Pfizer and Valneva reported topline Phase 3 VALOR trial data for their investigational 6 valent OspA based Lyme disease vaccine candidate, with efficacy readings in prespecified analyses and Pfizer planning regulatory submissions after reviewing the results and safety profile (Product related announcement).

VLA: Vaccine Partnerships And Guidance Will Drive Bullish Repricing Potential

Analysts have nudged their price target on Valneva slightly lower to about €6.96 from roughly €6.99, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings levels. What's in the News Elaris FlexCo signed an exclusive global license agreement for Valneva's Clostridioides difficile vaccine candidate VLA84, with plans to use the antigen technology in a next generation program and potential milestone and royalty payments tied to future development, regulatory and commercial outcomes (Key Developments).

VLA: Future Travel Vaccine Franchise And Real World Data Will Drive Reassessment

Analysts have reaffirmed their €10.00 price target for Valneva, with updated assumptions showing a slightly higher discount rate and profit margin, alongside a lower future P/E, suggesting a more balanced view of risk and earnings potential. What's in the News Valneva issued earnings guidance for 2026, expecting total revenues of €155 million to €170 million, with product sales of €145 million to €160 million.

VLA: Future Lyme Vaccine Milestones Will Shape Bullish Repricing Potential

Analysts have adjusted their fair value estimate for Valneva from €6.51 to about €6.99. This change reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.

VLA: Chikungunya Safety Setbacks Will Weigh On Long Term Earnings Potential

Analysts have reduced their price target on Valneva from €3.25 to €2.95, citing updated assumptions for revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Valneva and Instituto Butantan launched a Pilot Vaccination Strategy in Brazil using single shot chikungunya vaccine IXCHIQ, aiming for 20% to 40% coverage of adults aged 18 to 59 in ten municipalities as part of post marketing effectiveness and safety studies (Key Developments).

VLA: Future Vaccine Pipeline Progress Will Support Higher Market Reassessment

Analysts have lifted their fair value estimate for Valneva from €9.50 to €10.00, pointing to adjusted assumptions around discount rates, revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Valneva decided to voluntarily withdraw the BLA and IND for its chikungunya vaccine IXCHIQ in the US after the FDA suspended the license in August 2025 and later placed the IND on clinical hold following a newly reported foreign serious adverse event that may be plausibly related to vaccination, while causality has not been determined and no active vaccination studies are ongoing (company announcement).

VLA: Chikungunya Commercial Uncertainty Will Undermine Long Term Earnings Potential

Analysts have adjusted their price targets for Valneva, with updated assumptions that include a discount rate of 6.76%, revenue growth of 9.16%, a profit margin of 26.93% and a forward P/E of 13.87x, reflecting a recalibration of expectations around the company’s risk profile and earnings outlook. What's in the News Valneva and Serum Institute of India agreed to discontinue their license deal for the single shot chikungunya vaccine, with Valneva regaining full rights to manage supply and commercialization in endemic high risk countries within the funding framework agreed with CEPI and the European Union (Client Announcements).

VLA: Higher Long Term Profit Hopes Will Not Offset Rising Risk

Analysts have trimmed their price target for Valneva from €3.75 to €3.25, reflecting higher perceived risk despite more optimistic long term assumptions for revenue growth and profitability. What's in the News Positive Phase 2 antibody persistence and safety data in 304 children for single shot chikungunya vaccine IXCHIQ, supporting full dose selection and planned Phase 3 development in pediatrics (company announcement) Phase 2 Lyme disease vaccine candidate VLA15 shows strong booster response and favorable safety across age groups, reinforcing partnership with Pfizer ahead of planned 2026 BLA and MAA filings, subject to positive Phase 3 results (company announcement) Strategic reorganization to concentrate French operations in Lyon and close the Nantes site.

Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%

Oct 01
Subdued Growth No Barrier To Valneva SE (EPA:VLA) With Shares Advancing 29%

Is Valneva (EPA:VLA) Using Too Much Debt?

Sep 10
Is Valneva (EPA:VLA) Using Too Much Debt?

Rapid Lyme Vaccine Development And Rising Preventative Healthcare Will Shape Future Markets

Valneva's substantial improvement in net profit margin and sharp reduction in future P/E have led to a notable upward revision in the consensus analyst price target from €6.97 to €7.48. What's in the News Health Canada granted marketing authorization for IXCHIQ, Valneva’s single-dose chikungunya vaccine, for individuals aged 12 years and older, supported by robust antibody persistence and safety data.

Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Jul 24
Valneva SE's (EPA:VLA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
User avatar

Upcoming Lyme Vaccine Data Will Unlock Market Opportunities

Potential success of the Lyme disease vaccine could significantly boost future revenue and earnings through strategic regulatory filings and commercialization milestones.

Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%

Feb 20
Valneva SE (EPA:VLA) Analysts Just Slashed Next Year's Revenue Estimates By 13%

Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry

Feb 06
Valneva SE (EPA:VLA) Stock Catapults 35% Though Its Price And Business Still Lag The Industry

Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues

Nov 22
Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues

€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Nov 10
€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Sep 19
Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 17
Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

주주 수익률

VLAFR BiotechsFR 시장
7D-0.1%1.1%-0.6%
1Y-20.5%281.4%-0.2%

수익률 대 산업: VLA은 지난 1년 동안 281.4%의 수익을 기록한 French Biotechs 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: VLA은 지난 1년 동안 -0.2%를 기록한 French 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is VLA's price volatile compared to industry and market?
VLA volatility
VLA Average Weekly Movement13.4%
Biotechs Industry Average Movement8.7%
Market Average Movement5.4%
10% most volatile stocks in FR Market10.3%
10% least volatile stocks in FR Market2.9%

안정적인 주가: VLA의 주가는 지난 3개월 동안 French 시장보다 변동성이 컸습니다.

시간에 따른 변동성: VLA의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 French 종목 중 상위 75%보다 높습니다.

회사 소개

설립직원 수CEO웹사이트
1998674Thomas Lingelbachvalneva.com

백신 전문 기업인 발네바 SE는 미충족 수요가 있는 전염병 예방 백신을 개발, 제조 및 상용화하는 기업입니다. 일본뇌염 예방을 위한 불활화 베로 세포 배양 유래 일본뇌염 백신인 익시아로, 비브리오 콜레라 또는 장독소 생성 장출혈성 대장균으로 인한 설사 예방용 경구 백신인 듀코랄, 치쿤구니야 바이러스에 의한 질병 예방을 위한 1회 접종 생약독화 백신인 익치크/ VLA1553을 공급하고 있습니다. 또한 라임병을 일으키는 박테리아 보렐리아에 대한 백신 후보인 VLA15, 시겔라균에 의한 설사 감염인 이질에 대한 4가 바이오접합백신 후보인 S4V2, 모기 매개 바이러스 질환인 지카 바이러스에 대한 백신 후보인 VLA1601을 개발 중입니다; 인간 메타뉴모바이러스를 표적으로 하는 백신 후보물질인 VLA1554, 클로스트리디움 디피실 감염의 일차 증상 예방을 표적으로 하는 백신 후보물질인 VLA84, 엡스타인-바 바이러스 환자 치료를 위한 백신 후보물질인 VLA2112 등 다양한 백신 후보물질이 있습니다.

Valneva SE 기초 지표 요약

Valneva의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
VLA 기초 통계
시가총액€438.46m
순이익 (TTM)-€115.19m
매출 (TTM)€174.66m
2.5x
주가매출비율(P/S)
-3.8x
주가수익비율(P/E)

VLA는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
VLA 손익계산서 (TTM)
매출€174.66m
매출원가€192.44m
총이익-€17.78m
기타 비용€97.41m
순이익-€115.19m

최근 보고된 실적

Dec 31, 2025

다음 실적 발표일

May 13, 2026

주당순이익(EPS)-0.61
총이익률-10.18%
순이익률-65.95%
부채/자본 비율168.8%

VLA의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/02 11:12
종가2026/04/30 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Valneva SE는 15명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Vladimira UrbankovaErste Group Bank AG
Simon ScholesFirst Berlin Equity Research GmbH
Rajan SharmaGoldman Sachs